论文部分内容阅读
目的:探讨糖肾方对糖尿病肾病大鼠纤溶功能的影响。方法:Wistar大鼠利用单侧肾切除合并腹腔注射链脲佐菌素诱导大鼠糖尿病肾病模型,随机分为模型组、蒙诺组(0.833g/kg)、糖肾方大剂量组(2.67g/kg)和糖肾方小剂量组(1.33g/kg),每组10只;另取10只进行假手术后腹腔注射柠檬酸缓冲液作为空白组。各实验组每日灌胃给药1次,连续给药12周。每4周检测血糖和尿蛋白/肌酐水平。实验结束时处死大鼠,取血检测总胆固醇、甘油三酯、组织型纤溶酶原激活物(TPA)、纤溶酶原活化物抑制因子(PAI)、纤维蛋白降解产物(FDP)水平,取肾组织进行病理组织学观察。结果:糖肾方大剂量能显著降低模型大鼠尿蛋白/肌酐(P<0.05),减少血清胆固醇和甘油三酯水平(P<0.05,P<0.01);糖肾方大、小剂量均可显著上调TPA含量,下调PAI及FDP水平;减轻模型大鼠肾小球和肾小管间质损害。结论:糖肾方对糖尿病肾病大鼠具有肾保护作用,其作用机制可能与降低血脂代谢,调节纤溶功能有关。
Objective: To investigate the effect of Tangshen prescription on fibrinolytic function in rats with diabetic nephropathy. Methods: The model of diabetic nephropathy was induced by unilateral nephrectomy and intraperitoneal injection of streptozotocin in Wistar rats. The rats were randomly divided into model group, Monopril group (0.833g / kg), Tangshenfang high dose group (2.67g / kg) and Tangshenfang low dose group (1.33g / kg), with 10 rats in each group. Another 10 rats were injected intraperitoneally with citrate buffer as a blank group. The experimental group administered by gavage once daily for 12 weeks. Blood glucose and urine protein / creatinine levels were measured every 4 weeks. At the end of the experiment, the rats were sacrificed and blood was collected for determination of total cholesterol, triglycerides, tissue plasminogen activator (TPA), plasminogen activator inhibitor (PAI), fibrin degradation product (FDP) Kidney tissue was taken for histopathological observation. Results: The high dose of Tangshen Recipe could significantly reduce the urinary protein / creatinine (P <0.05), reduce the levels of serum cholesterol and triglyceride in model rats (P <0.05, P <0.01) Significantly increased TPA levels, down-regulated PAI and FDP levels; alleviated glomerular and tubular interstitial damage in model rats. Conclusion: Tangshen formula has a renal protective effect on rats with diabetic nephropathy, its mechanism may be related to lowering blood lipid metabolism and regulating fibrinolytic function.